ALT
Price
$5.17
Change
+$0.20 (+4.02%)
Updated
Apr 24 closing price
Capitalization
398.16M
13 days until earnings call
CRNX
Price
$33.41
Change
+$1.04 (+3.21%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
3.13B
13 days until earnings call
Ad is loading...

ALT vs CRNX

Header iconALT vs CRNX Comparison
Open Charts ALT vs CRNXBanner chart's image
Altimmune
Price$5.17
Change+$0.20 (+4.02%)
Volume$1.47M
Capitalization398.16M
Crinetics Pharmaceuticals
Price$33.41
Change+$1.04 (+3.21%)
Volume$26.63K
Capitalization3.13B
ALT vs CRNX Comparison Chart
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALT vs. CRNX commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Buy and CRNX is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (ALT: $5.17 vs. CRNX: $33.39)
Brand notoriety: ALT and CRNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 54% vs. CRNX: 89%
Market capitalization -- ALT: $398.16M vs. CRNX: $3.13B
ALT [@Biotechnology] is valued at $398.16M. CRNX’s [@Biotechnology] market capitalization is $3.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileCRNX’s FA Score has 0 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • CRNX’s FA Score: 0 green, 5 red.
According to our system of comparison, CRNX is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 5 TA indicator(s) are bullish while CRNX’s TA Score has 5 bullish TA indicator(s).

  • ALT’s TA Score: 5 bullish, 3 bearish.
  • CRNX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both ALT and CRNX are a good buy in the short-term.

Price Growth

ALT (@Biotechnology) experienced а +13.63% price change this week, while CRNX (@Biotechnology) price change was +9.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

ALT is expected to report earnings on Aug 07, 2025.

CRNX is expected to report earnings on Aug 08, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($3.13B) has a higher market cap than ALT($398M). ALT YTD gains are higher at: -28.294 vs. CRNX (-36.671). ALT has higher annual earnings (EBITDA): -94.81M vs. CRNX (-336.07M). CRNX has more cash in the bank: 1.35B vs. ALT (132M). ALT has less debt than CRNX: ALT (1.68M) vs CRNX (51.7M). CRNX has higher revenues than ALT: CRNX (1.04M) vs ALT (20K).
ALTCRNXALT / CRNX
Capitalization398M3.13B13%
EBITDA-94.81M-336.07M28%
Gain YTD-28.294-36.67177%
P/E RatioN/AN/A-
Revenue20K1.04M2%
Total Cash132M1.35B10%
Total Debt1.68M51.7M3%
FUNDAMENTALS RATINGS
ALT vs CRNX: Fundamental Ratings
ALT
CRNX
OUTLOOK RATING
1..100
1054
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
89
Overvalued
PROFIT vs RISK RATING
1..100
9058
SMR RATING
1..100
9476
PRICE GROWTH RATING
1..100
8683
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5014

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRNX's Valuation (89) in the Pharmaceuticals Major industry is in the same range as ALT (97) in the Miscellaneous Commercial Services industry. This means that CRNX’s stock grew similarly to ALT’s over the last 12 months.

CRNX's Profit vs Risk Rating (58) in the Pharmaceuticals Major industry is in the same range as ALT (90) in the Miscellaneous Commercial Services industry. This means that CRNX’s stock grew similarly to ALT’s over the last 12 months.

CRNX's SMR Rating (76) in the Pharmaceuticals Major industry is in the same range as ALT (94) in the Miscellaneous Commercial Services industry. This means that CRNX’s stock grew similarly to ALT’s over the last 12 months.

CRNX's Price Growth Rating (83) in the Pharmaceuticals Major industry is in the same range as ALT (86) in the Miscellaneous Commercial Services industry. This means that CRNX’s stock grew similarly to ALT’s over the last 12 months.

CRNX's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that CRNX’s stock grew similarly to ALT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTCRNX
RSI
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 9 days ago
89%
Bearish Trend 9 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FLDGX12.59N/A
N/A
Meeder Dynamic Allocation Retail
LMNVX114.12N/A
N/A
ClearBridge Value I
LMCHX30.27N/A
N/A
Lord Abbett Mid Cap Stock R6
FIFAX24.78N/A
N/A
American Funds Income Fund of Amer F3
DIERX40.03N/A
N/A
BNY Mellon International Core Equity I

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with DNLI. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
+3.55%
DNLI - CRNX
52%
Loosely correlated
+1.85%
XNCR - CRNX
52%
Loosely correlated
+2.07%
RVMD - CRNX
52%
Loosely correlated
+1.57%
TRDA - CRNX
52%
Loosely correlated
N/A
ETNB - CRNX
51%
Loosely correlated
+0.92%
More